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Failure to seroconvert 
after two doses of 
BNT162b2 SARS-CoV-2 
vaccine in a patient with 
uncontrolled HIV
SARS-CoV-2 infection elicits similar 
antibody responses in HIV-negative 
individuals and people living with 
HIV that is well controlled by anti-
retroviral therapy (ART).1 SARS-CoV-2 
vaccines, including the mRNA vaccine 
BNT162b2, are efficacious in clinical 
trials, inducing antibodies and T cells 
specific to the spike protein.2–4 However, 
vaccine responses in people living with 
HIV have been assessed only in those 
stable on ART.5 Immune function in 
people with HIV and uncontrolled 
HIV replication is impaired due to 
destruction of the CD4 T cells that help 
B cells during an antibody response. 
Immune responses to vaccines (eg, 
against influenza and hepatitis B) in 
people living with HIV are inferior to 
those in the general population.6 We 
present a case of one individual with 
uncontrolled HIV replication who 
did not respond to two doses of the 
BNT162b2 SARS-CoV-2 vaccine. 
The index patient, with advanced 
HIV, was recruited to a cohort study, 
along with 13 people living with 
HIV suppressed on ART (median 
CD4 count 590 cells per μL [SD 202; 
range 310–940]) and 43 HIV-negative 
controls, all of whom had received 
one or two doses of BNT162b2.1 The 
index patient had no history of SARS-
CoV-2 infection or AIDS-defining 
conditions and had already received 
two doses of BNT162b2 24 days apart. 
Blood samples were obtained 16 days 
and 44 days after the second dose 
(appendix p 2). At day 16, the patient’s 
HIV viral load was 831 764 copies 
per mL and CD4 count was 20 cells per 
μL (CD4% 4·6%; CD4/CD8 0·05). ART 
with bictegravir, emtricitabine, and 
tenofovir alafenamide and prophylaxis 
for opportunistic infections were 
initiated at day 16. At day 44 (29 days 
after ART initiation), HIV viral load 
was undetectable and CD4 count was 
70 cells per μL.  
Post-vaccine samples from 
the index patient showed no IgG 
reactivity against the S1 subunit of 
the spike protein by an in-house ELISA 
(appen dix pp 1–2).7 By contrast, an 
HIV-negative, SARS-CoV-2-naive 
participant had an S1-specific IgG titre 
of 43·4 μg/mL 44 days after the second 
dose of BNT162b2, consistent with the 
binding titres across the wider cohort, 
in which all participants produced S1-
specific IgG, even after only one dose 
(appendix pp 1–2). No SARS-CoV-2-
specific neutralisation was observed at 
either timepoint for the index patient. 
By contrast, the HIV-negative, SARS-
CoV-2-naive vaccine recipient had a 
neutralisation titre of 1/656 after the 
second dose. No quantifiable spike 
protein-specific T cells, evaluated via 
ELISpot (MAIPN4550; Merck Millipore, 
Darmstadt, Germany), were observed 
in the index patient compared with 
the HIV-negative control participant, 
sampled 44 days after the second 
dose, and a subsample of people 
living with well controlled, stable 
HIV after one dose of BNT162b2 
(appendix p 2). Although no spike 
protein-specific T cells were detected 
via intracellular cytokine staining 
in the index patient, responses 
against cytomegalovirus pp65 were 
dominated by CD8 T cells, strikingly so 
after ART (appendix p 2). The profound 
peripheral immune cell perturbations 
in the index patient were accompanied 
by increased frequencies of CD8 
T cells with a terminally differentiated 
effector memory phenotype (CCR-7– 
and CD45RA+) and an inverted CD4/
CD8 ratio, which could influence the 
size of T-cell responses to SARS-CoV-2.1 
In conclusion, an individual with pro-
found HIV-related immune dys function 
did not seroconvert to a SARS-CoV-2 
vaccine. We sug gest monitoring SARS-
CoV-2 seroconversion in people with 
advanced HIV and con sidering repeat 
vaccination upon HIV suppression 
and CD4 count improvement with 
ART. This case highlights an urgent 
need to establish correlates of vaccine 
efficacy in people living with HIV, 
particularly in those with suboptimal 
viral suppression or ongoing perturbed 
immune function, to better inform 
clinical management and guidelines.
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reporting HIV testing in the past year 
ranged from 15% (Philippines) to 
89% (Nepal). However, the percentage 
of transgender people with HIV 
receiving antiretroviral therapy was 
not reported, or low if available.4 
Hence, Asian countries need to include 
transgender people as a separate 
group in HIV surveillance programmes 
and expand current programmes to 
include smaller cities and rural areas.
Second, use of HIV pre vention 
services is low among transgender 
people in Asia. As of 2019, less 
than 50% of transgender people 
reportedly received a combined set 
of HIV prevention interventions 
in Bangladesh, Nepal, Pakistan, 
Philippines, and Sri Lanka.4 Data on 
the use of pre-exposure prophylaxis 
(PrEP) were consistently included 
with data from MSM in Asia.3 Our 
cross-sectional study reported in 
2020 also showed a low PrEP uptake 
among transfeminine people in 
China (24 [8·7%] of 277 people).5 
Additionally, societal stigma and 
discrimination consistently hindered 
transgender people’s access to PrEP 
and other HIV services in Asia.3,6 
Therefore, it is crucial to consider 
the socioecological systems that 
dictate access to HIV care and to 
plan data collection strategies 
accordingly. We suggest researchers 
collect interpersonal and structural-
level data through both quantitative 
and qualitative methods when 
considering health inequalities in 
transgender people.
Third, few data exist on mental 
health and gender-affirming inter-
ventions among transgender people 
in Asia.7 Using the gender minority 
stress framework, our study in China 
found that gender-identity-related 
stress can effect transgender people’s 
engagement with gender-affirming 
interventions and HIV prevention 
services.5 As access to HIV care services is 
interconnected with mental health and 
gender affirmation,8 we recommend 
collecting data related to these area to 
address health inequalities.
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Need for transgender-
specific data from Asia
In The Lancet HIV,  Venkatesan 
Chakrapani1 commented on the study 
by Adrian D Smith and colleagues2 
and suggested transgender-specific 
data collection to inform the redress 
of health inequalities. We believe 
heeding this call for transgender-
specific data could benefit efforts in 
Asia to identify gaps in HIV response 
for transgender people.
First, transgender-specific HIV 
care cascade data are scarce. This 
scarcity could be because the data 
are usually merged with data from 
men who have sex with men (MSM) 
or not reported due to negligence 
or not enough attention being paid 
to this group of people.3 Among the 
countries where data were available, 
HIV prevalence among transgender 
people reached 24·8% in 2019 in 
Indonesia, and increased in countries 
that used integrated biological 
and behavioural surveillance (eg, 
Cambodia, Malaysia, and Thailand).3,4 
The percentage of transgender people 
